This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients in the region” James Leech, Palette Life Sciences
SANTA BARBARA, Calif. and STOCKHOLM (PRWEB) July 14, 2020
Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced its latest distribution agreement with Gulf Horizon Co. Ltd. (GHIM). GHIM will distribute Palette’s product, Deflux, in Saudi Arabia. GHIM is a medical equipment company that provides hospitals with innovative medical devices for minimally invasive surgery in the Kingdom of Saudi Arabia (KSA). This new distribution agreement with GHIM further extends Palette’s global expansion efforts, and marks the first time Deflux has been directly registered within the KSA.
“This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients within the region,” said James Leech, Head of Corporate Development, Palette Life Sciences. “GHIM has vast experience and deep physician relationships within the KSA. We are confident that GHIM will be an excellent partner to aid in our delivery of high quality solutions to physicians and patients. Palette Life Sciences is dedicated to supporting physicians globally in their pursuit of improved patient outcomes. Palette and its network of partners are making several significant investments within local markets to improve physician access to Palette resources, including renewed product training and support."
For more information or to place an order within a GHIM territory, please contact a GHIM representative at email@example.com.
Deflux is a minimally invasive, outpatient treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR). VUR is a serious paediatric urinary condition in which urine refluxes from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilised Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection around the ureteral opening to prevent urine reflux. Deflux is indicated for children with all VUR grades and is the recommended first-line treatment for VUR.1 Separate study results show Deflux is an efficacious long-term (15 – 25 years) treatment option for VUR grade IV2 with up to 93% success rates after a one time injection and no post-injection febrile UTIs (19 month results).3 Deflux is the only minimally invasive VUR treatment approved globally across Australia, Canada, Europe, Latin American, Japan, New Zealand and the United States.
About Palette Life Sciences AB
Palette Life Sciences is a fully integrated life sciences company. Palette’s products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux®, Solesta® and Barrigel®. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, and Dallas, Texas. Learn more at http://www.palettelifesciences.com.
1. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infection in patients with vesicoureteral reflux. Curr Med Res Opin. 2007;23(4):S15-20.
2. Stenbäck A, Olafsdottir T, Sköldenberg E, Barker G, Läckgren G. Non-animal hyaluronic acid/dextranomer gel (Deflux®) endoscopic treatment in grade IV VUR results after 15-25 years: durable and effective. J Pediatr Urol. 2020.
3. Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. J Pediatr Urol. 2012;9(4)359-365.
Q-Med AB is the current legal manufacturer and holds the CE Mark.
Deflux®, GHIM®, NASHA®, and Palette Life Sciences™ are registered trademarks.
All rights reserved. APM209A